Some studies, while they inform us, nonetheless raise more questions than they answer. In this issue, Baldessarini et al. present provocative information for both clinicians and researchers in their article "Illness Risk Following Rapid Versus Gradual Discontinuation of Antidepressants" (1). The study is not a controlled trial of an intervention, but rather, like much informative clinical research, it is essentially a detailed observation of patients. Patients with mood and anxiety disorders were carefully followed at clinics in Sardinia while they were treated with antidepressants. The study extended from the era of the tricyclic antidepressants to the modern era of selective serotonin reuptake inhibitors. Abrupt discontinuation of medication, usually initiated by patients themselves, was more likely to result in the return of depression within several months, compared to tapering the dosage over several weeks, generally recommended by physicians, which resulted in less likelihood of relapse. All patients included in the study had close to normal mood at the time of medication discontinuation, regardless of who made the decision to stop treatment. Patients whose antidepressants were stopped because of emerging mania were not included in the study. Even when a tapering regimen was used, medications with short half-lives, like paroxetine and venlafaxine, were more likely to produce early relapse than the longer-acting medications, including the tricyclics.